Statements (22)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:activeIngredient |
gptkb:tetrahydrocannabinol
cannabidiol |
| gptkbp:administeredBy |
oral route
|
| gptkbp:availableOn |
prescription
|
| gptkbp:clinicalTrialPhase |
ongoing
|
| gptkbp:developedBy |
gptkb:MGC_Pharmaceuticals
|
| gptkbp:form |
oral solution
|
| gptkbp:intendedUse |
treatment of epilepsy
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:marketedIn |
gptkb:Australia
gptkb:Ireland gptkb:United_Kingdom |
| gptkbp:status |
gptkb:investigational_drug
|
| gptkbp:THCContent |
100 mg/mL
less than 0.3% |
| gptkbp:usedFor |
gptkb:Dravet_syndrome
gptkb:Lennox-Gastaut_syndrome drug-resistant epilepsy |
| gptkbp:bfsParent |
gptkb:MGC_Pharmaceuticals
|
| gptkbp:bfsLayer |
7
|
| https://www.w3.org/2000/01/rdf-schema#label |
CannEpil
|